Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
2119
mi
from 91732
Pittsburgh, PA
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
2119
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
CCI-779 in Treating Patients With Malignant Glioma
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
UCSF Comprehensive Cancer Center
356
mi
from 91732
San Francisco, CA
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
UCSF Comprehensive Cancer Center
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
2277
mi
from 91732
Bethesda, MD
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
NCI - Neuro-Oncology Branch
mi
from 91732
Bethesda, MD
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
NCI - Neuro-Oncology Branch
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
2575
mi
from 91732
Boston, MA
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
2575
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
2119
mi
from 91732
Pittsburgh, PA
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
2119
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas
1221
mi
from 91732
Dallas, TX
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas
1221
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center - Dallas
1223
mi
from 91732
Dallas, TX
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center - Dallas
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center - Dallas
1223
mi
from 91732
Dallas, TX
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center - Dallas
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center - Dallas
1223
mi
from 91732
Dallas, TX
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center - Dallas
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
UCSF Cancer Center and Cancer Research Institute
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials